Surendra K Gupta

US Patent:

6762035, Jul 13, 2004

Filed:

Feb 4, 2002

Appl. No.:

10/067660

Inventors:

Surendra K. Gupta - Laguna Niguel CA 92677

International Classification:

C12Q 132

US Classification:

435 26, 435 4, 435829, 435968, 435970

Abstract:

A method for monitoring the progress of fat loss in a patient during a weight loss program which comprises, contacting a body fluid sample from said patient with a solid test strip to provide a color indication of the presence in said body fluid of -hydroxybutyrate, optionally together with acetoacetate and/or acetone.

US Patent:

20040043376, Mar 4, 2004

Filed:

Aug 25, 2003

Appl. No.:

10/646763

Inventors:

Surendra Gupta - Laguna Niguel CA, US

International Classification:

C12Q001/00
C12Q001/32

US Classification:

435/004000, 435/026000

Abstract:

Disposable test strips and a wet chemistry method for measuring each of -hydroxybutyrate alone, combined -hydroxybutyrate and acetoacetate or total ketone bodies (i.e., -hydroxybutyrate, acetoacetate and acetone) in human bodily fluid samples, including but not limited to urine, saliva or sweat are described. The test strips need only be dipped in the sample and can be used by anyone in almost any milieu. Measurement can be made electrochemically, spectrophotometrically, fluorometrically or by comparision to a color standard. Combined acetoacetate and -hydroxybutyrate which account for 97-98% of total ketone bodies and may be measured in a cyclic reaction that occurs at pH about 7.0 to about 8.3 with -hydroxybutyrate dehydrogenase, (-HBD), nicotinamide adenine dinucleotide, a tetrazolium dye precursor and an electron mediator. Using this reaction, false positive results obtained from urine samples taken from patients on sulfhydryl drugs are avoided. -HBD from some sources was found to cause false negative results in samples (e.g. urine) containing high chloride content due to chloride inhibition of -HBD. Using a simple test for chloride inhibition, it was found that -HBD from Alcaligenes is not so inhibited. Using either -HBD that is not inhibited by chloride or using 10-20 times the normal concentration of this enzyme eliminates false negatives in samples having substantial chloride content, such as urine, both in the reaction described above and in other reactions disclosed for measuring each of -hydroxybutyrate alone, combined -hydroxybutyrate and acetoacetate and total ketone bodies, all of which reactions occur in the pH range of about 8.6 to about 9.5.

US Patent:

20050214161, Sep 29, 2005

Filed:

Mar 23, 2004

Appl. No.:

10/806461

Inventors:

Surendra Gupta - Laguna Niguel CA, US

International Classification:

G01N031/22

US Classification:

422056000

Abstract:

The invention consists of a test device for simultaneous measurement of multiple analytes in one sample where the liquid sample is applied to a matrix at the central area of the device which is connected to multiple arms, and each of the arms contains specific reagents in dry form for measurement of a particular analyte. The sample travels from the center uniformly and quickly to the reagent site on each arm and produces a measurable signal that may be a change in electrical charge or current, fluorescence, or, preferably, color. A color change can be detected visually or measured quantitatively using a suitable reflectance meter. The sample may be a small amount of whole blood obtained e.g., from a finger puncture or it may be urine, saliva, any other bodily fluid, environmental water, or any other fluid upon which rapid, simultaneous testing of levels of different components is desired. According to the invention, a disease specific panel for kidney, liver, heart, lipid disorders or for early detection of dysfunction of general health can be performed at or near the patients' site and can provide instant results. Similarly, rapid simultaneous testing of water samples is desirable under many circumstances.

US Patent:

20110230398, Sep 22, 2011

Filed:

Mar 19, 2010

Appl. No.:

12/727339

Inventors:

Surendra K. Gupta - Laguna Niguel CA, US

International Classification:

A61K 38/00
C07K 14/00
C07K 2/00
A61P 3/04

US Classification:

514 48, 530350, 530300, 514 69, 514 74

Abstract:

Apoliporotein C-II or any active fraction of its amino acid sequence that activates lipoprotein lipase (LPL) in mammals. Increase in activity of LPL can increase expenditure of energy, and therefore an activator of LPL can be an effective agent for the prevention or treatment of obesity or related metabolic disorders, including cardiovascular disease, diabetes and hypertension in mammals including domestic pets and humans. Apolipoprotein C-II or its active fractions can be used as a diet supplement in the form of fortification to a natural product such as milk, cereal, beverage; as a nutritional supplement; or as a therapeutic agent in conventional forms of administration.

US Patent:

51889552, Feb 23, 1993

Filed:

Jan 21, 1992

Appl. No.:

7/823452

Inventors:

Aurora F. DeCastro - Union MI
Surendra K. Gupta - Elkhart IN
Steven M. Shantz - Goshen IN

Assignee:

GDS Technology, Inc. - Elkhart IN

International Classification:

C12N 996
C12N 978

US Classification:

435188

Abstract:

Arylacylamidase can be stabilized by inhibiting conformational changes using either o-cresol or benzoic acid or salts of benzoic acid as a stabilizing agent. The compositions show significantly enhanced stability of arylacylamidase in aqueous solution, lyophilized, and solid-phase formats.

US Patent:

51889412, Feb 23, 1993

Filed:

Dec 31, 1991

Appl. No.:

7/815590

Inventors:

Aurora F. deCastro - Union MI
Surendra K. Gupta - Elkhart IN
Arun K. Agarwal - Elkhart IN

Assignee:

GDS Technology, Inc. - Elkhart IN

International Classification:

C12Q 144

US Classification:

435 19

Abstract:

The present invention provides a new methodology and test composition for determining the presence of theophylline in test samples. The methodology employs enzymes that utilize or recognize theophylline as a substrate to measure the concentration thereof in samples, including body fluids. This new approach utilizes enzymes as opposed to traditional methods which use antibodies for the recognition of theophylline. The enzymatic approach to theophylline determination is quick, simple and convenient and allows test systems to be made in liquid as well as in dry-chemistry formats. Various protocols, systems or methodologies may be used for assaying and relating the results to the amount of theophylline present. Methods for obtaining theophylline utilizing or recognizing enzymes are also described.

US Patent:

42594405, Mar 31, 1981

Filed:

May 21, 1979

Appl. No.:

6/040559

Inventors:

Surendra K. Gupta - Elkhart IN
Panna R. Chaudhari - Elkhart IN

Assignee:

Miles Laboratories, Inc. - Elkhart IN

International Classification:

C12Q 148
C12Q 144

US Classification:

435 15

Abstract:

A method and composition for the hydrolysis and assay of triglycerides are disclosed. The method includes the steps of adding lipase and cholesterol esterase to a triglyceride in combination with a glycerol assay system and determining the amount of triglycerides present based on the amount of glycerol produced. The composition includes a mixture of lipase, cholesterol esterase and a glycerol assay system.

US Patent:

49992880, Mar 12, 1991

Filed:

Oct 28, 1987

Appl. No.:

7/116169

Inventors:

Aurora F. deCastro - Union MI
Surendra K. Gupta - Elkhart IN
Steven M. Shantz - Goshen IN

Assignee:

GDS Technology, Inc. - Elkhart IN

International Classification:

C12Q 134
C12Q 128
C12N 996

US Classification:

435 18

Abstract:

A method and unitized test composition is described for the estimation of an anilide in which the enzymatic hydrolysis of the anilide and colorimetric quantitation of aniline or aniline derivative can be done simultaneously. The hydrolysis of the anilide is catalyzed by a known enzyme, arylacylamidase, E. C. 3. 5. 1. 13. Stabilization of the enzyme is provided by the addition of controlled amounts of a compound containing alcoholic and/or aromatic groups such as ortho-cresol, isopropanol or benzoate. Basically, the unitized test composition comprises (i) arylacylamidase, (ii) a controlled amount of an organic compound containing alcoholic and/or aromatic groups which acts as both a stabilizer for the arylacylamidase and forms a colored product with aniline, and (iii) a novel oxidant/catalytic agent for accelerating color development. The benefit of such methodology results in a one step addition of the complete reagent to the sample, serum or matrix containing the anilide as opposed to a several step addition. The consequence of this is that only one reagent channel is required to perform the test in an automated analyzer as opposed to the usual requirement that several channels be utilized.